Navigation Links
New Polio Vaccine Shows Major Advantages: Study
Date:10/26/2010

TUESDAY, Oct. 26 (HealthDay News) -- A new bivalent oral vaccine that targets two deadly strains of polio -- types 1 and 3 -- triggers a stronger immune response than the existing trivalent vaccine and an immune response that's similar to monovalent vaccines, a new study shows.

Use of trivalent and monovalent vaccines has reduced the number of countries where polio is endemic from more than 125 in 1988 to just four today. Transmission of polio virus types 1 and 3 persists in parts of Afghanistan, Pakistan, India and Nigeria.

The bivalent oral vaccine is already widely used in efforts to halt transmission of polio virus types 1 and 3, but this study set out to examine whether it triggers as much immunity as the other vaccines.

Between August and December 2008, researchers gave 830 newborns in India either the monovalent, bivalent or trivalent vaccines in two doses, including one at birth and one 30 days later. Antibody levels were measured in blood samples before vaccination and after the first and second doses of the vaccines.

Overall, the immune response induced by the bivalent vaccine was significantly higher than the trivalent vaccine and similar to the monovalent vaccine, the investigators found.

The study was released online Oct. 25 in advance of publication in an upcoming print issue of The Lancet.

"The major advantages of the bivalent vaccine ... is that it will enhance individual and population immunity simultaneously for both poliovirus types 1 and 3, without any serious loss in immunogenicity compared with the [monovalent vaccines]," the researchers said in a news release from the publisher.

More information

The American Academy of Family Physicians has more about polio vaccine.

-- Robert Preidt

SOURCE: The Lancet, news release, Oct. 25, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Rotary International and I Imagine Studio Have Teamed up to Helps Kick Polio out of Africa
2. Polio outbreak in Tajikistan is cause for alarm
3. Vaccine May Prevent TB in People With HIV
4. Vaccine Not Fail-Safe in Ongoing Mumps Outbreak
5. New strategy produces promising advance in cancer vaccines
6. Screens, Vaccine for HPV Less Beneficial in Older Women
7. New Technology Could Widen Reach of Vaccines
8. Texas-based consortium announces groundbreaking vaccine research program
9. The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies Failure to Provide Adequate Safety Research
10. Possible vaccine for mesothelioma proven safe
11. Groundbreaking research to find vaccine for hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Polio Vaccine Shows Major Advantages: Study
(Date:3/29/2017)... , ... March 29, 2017 , ... ... with or without a referral to new patients from Burnaby, BC. Patients in ... other full mouth reconstruction services, can see the esteemed team at Wall Centre ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or without ... efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, treatment with ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing Practices (GMPs) ... first ANSI-approved GMP standard for dietary supplements this spring, is hiring an ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... An inventor ... "The rubber bands used in conjunction with my braces always rubbed against the ... a way to prevent this problem." The O.B.S. was the result of his ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)...  Glenmark Pharmaceuticals, a global pharmaceutical company, today ... fixed-dose combination of mometasone furoate (25 mcg) and ... nasal spray being studied for the treatment of ... recently completed Phase 3 trial assessing the efficacy ... mometasone, olopatadine or placebo. "We continue ...
(Date:3/29/2017)... , March 29, 2017  The Pharmaceutical Care Management ... new PhRMA report on patient out-of-pocket spending: ... and Medicaid Services (CMS), the average amount spent out-of-pocket ... of drug spending in 2016, down from 23% in ... pricing problem, not a coverage problem. Health plans don,t ...
(Date:3/29/2017)...  NuVasive, Inc. (NASDAQ: NUVA), a leading medical ... minimally disruptive, procedurally-integrated solutions, today announced U.S. Food ... CoRoent® Small Interbody™ System indicated for intervertebral body ... spine. This marks the first U.S. clearance for ... to four contiguous levels. Cervical radiculopathy ...
Breaking Medicine Technology: